Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

• Published in: The New England journal of medicine Vol. 390; no. 10; pp. 875 - 888
• Main Authors: Powles, Thomas, Valderrama, Begoña P., Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, Hoffman-Censits, Jean, Iyer, Gopa, Vulsteke, Christof, Park, Se Hoon, Shin, Sang Joon, Castellano, Daniel, Fornarini, Giuseppe, Li, Jian-Ri, Gümüş, Mahmut, Mar, Nataliya, Loriot, Yohann, Fléchon, Aude, Duran, Ignacio, Drakaki, Alexandra, Narayanan, Sujata, Yu, Xuesong, Gorla, Seema, Homet Moreno, Blanca, van der Heijden, Michiel S.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 07.03.2024
• Subjects: Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Bladder cancer; Body weight; Cancer; Carboplatin; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carboplatin - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - pathology; Carcinoma, Transitional Cell - secondary; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Clinical outcomes; Drug dosages; Gemcitabine; Gemcitabine - administration & dosage; Gemcitabine - adverse effects; Gemcitabine - therapeutic use; Genitourinary Cancer; Hematology; Humans; Immunotherapy; Metastases; Metastasis; Monoclonal antibodies; Oncology; Patients; Pembrolizumab; Platinum; Prostate Disease; Prostate Disease General; Safety; Survival; Survival Analysis; Targeted cancer therapy; Treatments in Oncology; Urinary Bladder Neoplasms; Urologic Neoplasms - drug therapy; Urologic Neoplasms - pathology; Urologic Neoplasms - secondary; Urology; Urothelial cancer; Urothelial carcinoma; United States > US
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2312117

In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment.